Identification of Apo B48 and other novel biomarkers in amyotrophic lateral sclerosis patient fibroblasts

Biomark Med. 2016 May;10(5):453-62. doi: 10.2217/bmm-2016-0025. Epub 2016 Apr 13.


Aim: Amyotrophic lateral sclerosis (ALS) is a debilitating fatal neurodegenerative disorder. 90-95% of ALS cases are sporadic with no clear risk factors associated with the disease. Identification of biomarkers associated with ALS may lead to early detection and make it more amenable to therapeutic intervention.

Materials & methods: SILAC was used to quantitatively analyze the proteomes of ALS and control human fibroblasts.

Results: Out of total of 861 proteins identified, 33 were found to be differentially regulated. ApoB48 and Hsp20 were downregulated, while Fibulin-1 was upregulated.

Conclusion: We report the differential regulation of these proteins in ALS fibroblasts, and their potential as novel biomarkers and possible drug targets for ALS.

Keywords: Apo B48; SILAC; amyotrophic lateral sclerosis (ALS); biomarker; mass spectrometry; proteomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amyotrophic Lateral Sclerosis / diagnosis*
  • Amyotrophic Lateral Sclerosis / metabolism
  • Biomarkers / metabolism*
  • Calcium-Binding Proteins / metabolism
  • Cells, Cultured
  • Chromatography, High Pressure Liquid
  • Down-Regulation
  • Female
  • Fibroblasts / cytology
  • Fibroblasts / metabolism
  • HSP20 Heat-Shock Proteins / metabolism
  • Humans
  • Male
  • Metabolic Networks and Pathways
  • Middle Aged
  • Proteomics
  • Receptors, Lipoprotein / metabolism*
  • Tandem Mass Spectrometry
  • Up-Regulation


  • Biomarkers
  • Calcium-Binding Proteins
  • HSP20 Heat-Shock Proteins
  • Receptors, Lipoprotein
  • apo B48 receptor
  • fibulin